Neoantigen Immunogenicity Landscapes and Evolution of Tumor Ecosystems During Immunotherapy with Nivolumab
Neoantigen Immunogenicity Landscapes and Evolution of Tumor Ecosystems During Immunotherapy with Nivolumab
- 18/08/2023
- 200 samples
- DAC: EGAC00001003387
- Technology: Illumina HiSeq 4000
Clinical data will be shared at the discretion of Bristol Myers Squib; please contact Dr. William Geese william.geese@bms.com
Clinical data will be shared at the discretion of Bristol Myers Squib; please contact Dr. William Geese william.geese@bms.com
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001007508 | Other | |
| EGAS00001007509 | Other |
